A little more than two weeks ago biotech giant Celgene (NASDAQ: CELG ) delivered another smashing success of a quarter, at least along the lines of what the initial numbers entailed.

For the quarter, Celgene, which has been expanding the indications of existing medications in its product portfolio while also advancing its pipeline and introducing new therapies to pharmacy shelves, reported a 17% increase in total revenue to $1.87 billion from $1.6 billion in the year-ago period, while adjusted earnings per share increased 18% to $0.90 from $0.76.